DrugPatentWatch Database Preview
Blueprint Medicines Company Profile
» See Plans and Pricing
What is the competitive landscape for BLUEPRINT MEDICINES, and what generic alternatives to BLUEPRINT MEDICINES drugs are available?
BLUEPRINT MEDICINES has two approved drugs.
There are four US patents protecting BLUEPRINT MEDICINES drugs.
There are fifty-one patent family members on BLUEPRINT MEDICINES drugs in thirty-one countries.
Summary for Blueprint Medicines
| International Patents: | 51 |
| US Patents: | 4 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Blueprint Medicines
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-001 | Jan 9, 2020 | RX | Yes | No | 9,994,575 | Start Trial | Y | Y | Start Trial | ||
| Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-003 | Jan 9, 2020 | RX | Yes | Yes | 9,200,002 | Start Trial | Y | Y | Start Trial | ||
| Blueprint Medicines | GAVRETO | pralsetinib | CAPSULE;ORAL | 213721-001 | Sep 4, 2020 | RX | Yes | Yes | 10,030,005 | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Blueprint Medicines Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3409674 | Start Trial |
| Canada | 3003721 | Start Trial |
| Ecuador | SP18041935 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
